Psychotropic Medication Advisory Committee

Warning!

It seems that JavaScript is not working in your browser. It could be because it is not supported, or that JavaScript is intentionally disabled. Some of the features on CT.gov will not function properly with out javascript enabled.

Settings Menu

Language
High Contrast
High Contrast Mode On or Off switch
Font Size
Disclaimer

Stay informed about coronavirus (COVID-19): Connecticut residents are urged to continue taking precautions to prevent the spread of COVID-19. For the latest information and guidance, visit ct.gov/coronavirus.

NOTICE: Have a question concerning the Coronavirus and the Connecticut DCF? E-Mail us: DCF.COVID-19@ct.gov

Psychotropic Medication Advisory Committee (PMAC)

PMAC E-Mail: getmeds.dcf@ct.gov

The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications: FDA Safety Communication

2020 Minutes

March
February
January

2019 Minutes

December
November
October
September
May
April
March
February
January

Archived Meeting Minutes

Handouts:

Appendix II Psychotropic Medication Monitoring Protocols (June 2020)
CYP Metabolism of Psychotropic Medications
DCF and PMAC Position Paper on Supplements (September 2019)
Drug List - search by Generic or Brand names (June 2020)
Drug Review and Decision History by Date (July 2015)
Drug Review and Decision History by Drug (July 2015)
Guidelines for Psychotropic Medication Use in Children and Adolescents

DCF and PMAC position paper on supplements edited 9619